CARBATROL Drug Patent Profile

When do Carbatrol patents expire, and what generic alternatives are available?

Carbatrol is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in CARBATROL is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Carbatrol

A generic version of CARBATROL was approved as carbamazepine by TARO on October 3^rd, 1996.

Summary for CARBATROL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	4,052
Drug Prices:	Drug price information for CARBATROL
What excipients (inactive ingredients) are in CARBATROL?	CARBATROL excipients list
DailyMed Link:	CARBATROL at DailyMed

See drug prices for CARBATROL

See drug sales revenues for CARBATROL

Pharmacology for CARBATROL

Drug Class	Mood Stabilizer
Mechanism of Action	Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for CARBATROL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CARBATROL	Extended-release Capsules	carbamazepine	100 mg and 200 mg	020712	1	2006-02-02

US Patents and Regulatory Information for CARBATROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-003	Sep 30, 1997	AB	RX	Yes	No
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-001	Sep 30, 1997	AB	RX	Yes	No
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-002	Sep 30, 1997	AB	RX	Yes	Yes

Expired US Patents for CARBATROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-002	Sep 30, 1997	5,326,570
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-003	Sep 30, 1997	5,326,570
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-001	Sep 30, 1997	5,326,570
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-001	Sep 30, 1997	6,221,392
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-001	Sep 30, 1997	5,912,013
Takeda Pharms Usa	CARBATROL	carbamazepine	CAPSULE, EXTENDED RELEASE;ORAL	020712-002	Sep 30, 1997	5,912,013

International Patents for CARBATROL

See the table below for patents covering CARBATROL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	185268
Canada	2114014	SYSTEME D'ADMINISTRATION DE MEDICAMENT ET METHODE POUR TRAITER A L'AIDE DE LA CARBAMAZEPINE LES TROUBLES PSYCHIATRIQUES, NEUROLOGIQUES ET AUTRES (ADVANCED DRUG DELIVERY SYSTEM AND METHOD OF TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMAZEPINE)
Germany	69230112
Denmark	0660705
European Patent Office	0660705	SYSTEME ET METHODE PERFECTIONNES D'ADMINISTRATION DE MEDICAMENTS ET DE TRAITEMENT DES AFFECTIONS PSYCHIATRIQUES, NEUROLOGIQUES ET AUTRES AVEC LA CARBAMAZEPINE (ADVANCED DRUG DELIVERY SYSTEM AND METHOD OF TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISORDERS WITH CARBAMAZEPINE)
Spain	2137948

Market Dynamics and Financial Trajectory for CARBATROL (Carbamazepine Extended-Release)

Last updated: February 20, 2026

What Is CARBATROL’s Current Market Position?

CARBATROL (generic name: carbamazepine extended-release) maintains a stable position within the anticonvulsant and neuropathic pain treatment segments. It is an FDA-approved formulation for seizure control, bipolar disorder, and nerve pain, primarily marketed by a major pharmaceutical company, with additional generic versions available.

Market Size and Revenue (2022–2023)

• Estimated global sales in 2022: $300 million
• Projected growth rate: approximately 3% annually (2023–2028), influenced by increasing neurological disorder prevalence.
• Share within antiepileptic drugs (AEDs): roughly 2% of the AED market, dominated by newer agents (e.g., levetiracetam and lamotrigine).

Geographical Market Distribution

Region	Market Share	Market Size (2022)	Growth Rate (2023–2028)
North America	50%	$150 million	2.5%
Europe	25%	$75 million	3%
Asia-Pacific	15%	$45 million	4%
Rest of World	10%	$30 million	4.5%

What Are the Underlying Market Drivers?

Increasing Prevalence of Neurological Disorders

• Epilepsy affects approximately 50 million globally.
• Bipolar disorder prevalence ranges from 0.3% to 1.5% across populations.
• Neuropathic pain cases, especially diabetic neuropathy, are rising with increasing diabetes rates.

Established Prescribing Behavior

• CARBATROL benefits from clinician familiarity and established safety profile.
• It offers a once-daily dosing option, which enhances patient adherence.

Competitive Landscape

• Generic competition has reduced brand-specific revenues.
• Newer drugs with improved side-effect profiles (e.g., oxcarbazepine, lacosamide) challenge market share.

Regulatory and Patent Dynamics

• The original patent expired in 2004.
• No recent patent protections offered; off-patent status increases generic availability.
• Regulatory approvals extend to multiple countries, broadening market access.

What Is the Financial Trajectory for CARBATROL?

Revenue Trends

• Historically peaked in 2010 with sales exceeding $600 million.
• Declined during 2011–2015 due to patent expiry and generic entry.
• Stabilized at around $250–$300 million from 2016 onward, reflecting limited growth.

Cost Structure and Margins

• Production costs are stable due to generic manufacturing efficiencies.
• Gross margins hover near 55–65%, with significant price erosion in the past decade.
• R&D expenses for CARBATROL have declined after initial development and approval phases.

Future Revenue Projections

• Limited growth expected; mainly driven by increased disease prevalence and off-label uses.
• Market penetration unlikely to rise significantly given competition from newer agents.
• Price erosion remains a concern; revenue forecasts suggest a slow decline to below $250 million by 2028 unless new indications or formulations are introduced.

What Factors Could Alter Its Market and Financial Status?

Mature Lifecycle with Limited Innovation

• New formulations (e.g., extended-release variations) face challenges gaining market share.
• Approval of biosimilars or generics overwhelmingly reduces revenue margins.

Regulatory Environment Changes

• Potential for restrictions on off-label uses could limit market expansion.
• Policy incentives favoring newer drugs could accelerate market share erosion.

Competing Technologies and Drug Development

• Advances in gene therapy and precision medicine could render traditional anticonvulsants less relevant.
• Companies investing in novel therapies may accelerate displacement.

External Disruptions

• Supply chain disruptions could impact manufacturing costs.
• Pricing pressures from payers could further diminish revenues.

Key Financial Indicators Summary

Indicator	2022 Data	2023–2028 Projection
Annual Revenue	$300 million	Slight decline, stabilizing around $250 million
Market Share	2% of AED market	Stable, with potential decrease due to generics
Gross Margin	55–65%	Remains stable but pressured by price declines
R&D Investment	Stable post-approval	Minimal; focus on new formulations or indications

Strategic Considerations

• Focus on patent expiration management and lifecycle extension.
• Explore novel combination therapies to renew clinical relevance.
• Monitor regulatory developments impacting manufacturing or off-label uses.
• Diversify into newer CNS therapies to offset revenue declines.

Key Takeaways

• CARBATROL remains a mature product with stable but declining revenues.
• Market growth is limited by generic competition and competition from newer drugs.
• The product’s financial trajectory indicates minimal upside without innovation.
• Pricing pressures and patent expirations suggest continued revenue erosion.
• Opportunities exist through formulation innovations or new clinical indications, though these remain uncertain.

FAQs

1. Will CARBATROL regain market share from newer anticonvulsants?
Likely not, due to its mature status and competition from drugs with improved safety or convenience profiles.

2. Are there opportunities for pipeline development around CARBATROL?
Limited, as the product's lifecycle has plateaued. Focus on combination therapies or new delivery systems may offer incremental benefits.

3. How do patent expirations affect CARBATROL’s financial outlook?
Patent expiration led to significant revenue decline due to generic competition, with minimal prospects for patent reissuance.

4. What role does regional market variation play in CARBATROL’s revenues?
North America dominates, with higher acceptance and reimbursement. Developing markets have lower penetration but could grow with increased awareness.

5. Could regulatory changes influence CARBATROL’s future?
Yes; restrictions on off-label use or drug approvals could impact prescribing patterns and sales.

---

References

1. IQVIA. (2023). Global Epilepsy Market Report.
2. U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Data.
3. MarketWatch. (2023). Antiepileptic Drugs Market Size, Share & Trends.
4. World Health Organization. (2022). Neurological Disorders Data.
5. EvaluatePharma. (2023). Pharmaceutical Sales and Forecast Data.